An interventional study of Medtronic Evolut FX and Edwards Sapien 3 Ultra Resilia in Aortic Stenosis, sponsored by Christian Juhl Terkelsen. Active, not recruiting at 1 site in Denmark. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-25.
Sponsored by Christian Juhl Terkelsen · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 73 studies in Aortic Valve Stenosis with a site in Denmark — 13 open to participants now, 28 under way, none of them phase 3. Aortic Valve Stenosis · Denmark.
Among the 73 studies in Aortic Valve Stenosis with a site in Denmark, this one is the 6th largest by enrollment of the 40 interventional ones that give a count, is one of 7 that started in 2024, is one of 28 with no phase, reaches primary completion later than 18 of the 27 other live ones, and was the 66th registered.
1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.
Browse Aortic Valve Stenosis studies →13 of the 73 studies in Aortic Valve Stenosis with a site in Denmark are open now. Recruiting first, the newest first:
Copenhagen University Hospital, Rigshospitalet · Sites in Denmark, Sweden
Ages 18+
Anteris Technologies Ltd. · Sites in Denmark
Ages 18+
Ole De Backer · Sites in Denmark, Belgium, Finland and 3 more countries
Ages 18+
Rigshospitalet, Denmark · Sites in Denmark
Sahajanand Medical Technologies Limited · Sites in Denmark
Ages 18–99
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
73 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 3 · Phase 4 7
First in 2005; this study’s year is marked. 7 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,370 is above the median of 126 across 555 interventional studies indexed under Aortic Valve Stenosis.
Median enrollment 214 across the 40 interventional studies, 200 across the 33 observational. Of the 37 that completed or were terminated, 10 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 73 have an industry lead sponsor. The 10 most frequent:
Christian Juhl Terkelsen is the lead sponsor of 2 studies on the registry; none are open to participants now.
Christian Juhl Terkelsen has 1 study filed under Aortic Valve Stenosis — fewer than ten, so there is no comparison to draw.
6 of the studies in Aortic Valve Stenosis with a site in Denmark that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04913870Institut universitaire de cardiologie et de pneumologie de Québec, University LavalAngiotensin Receptor Blockers in Aortic Stenosis | 2027-02 |
| NCT05932615Abbott Medical DevicesENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation | 2027-04 |
| NCT05758662St. Antonius HospitalThe Effect of Subclinical Leaflet Thrombosis and Prosthesis Type on Transcatheter Aortic Valve Degeneration (POPular PET TAVI) | 2027-06 |
| NCT06638268Rigshospitalet, DenmarkTranscatheter AortiC Valve Implantation in aorTic stenosIs CardiogenIc Shock | 2027-07-01 |
| NCT06470022Christian Juhl TerkelsenComparison of Evolut FX Versus Sapien 3 Ultra Resilia. | 2027-07-14 |
Add all 6 to your calendar (.ics) → With an account.
Among the 73 studies in Aortic Valve Stenosis with a site in Denmark, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To compare outcome in patients randomized to treatment with Evolut FX versus Sapien 3 Ultra Resilia.
The purpose of the "Compare-TAVI" organization is to ensure a continuous comparison of the TAVI-valves implanted, and to monitor long-term valve performances.
Purpose of present study:
To compare outcome in patients randomized to treatment with Evolut FX versus Sapien 3 Ultra Resilia.
Hypotheses:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
None
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TAVI procedure performed with Medtronic Evolut FX
Device: Medtronic Evolut FX
TAVI procedure performed with Edwards Sapien Ultra 3 Resilia
Device: Edwards Sapien 3 Ultra Resilia
TAVI performed with Medtronic Evolut FX
TAVI performed with Edwards Sapien 3 Ultra Resilia
Mortality, stroke, moderate/major aortic regurgitation, moderate/severe THV deterioration
The primary composite endpoint is at one-year, and a non-inferiority test is performed. See separate statistical analysis plan. Separate analyses of each component of the primary outcome will be presented, in accordance with the FDA guidelines and EMA guidelines, i.e. mortality, stroke, moderate/severe aortic regurgitation and moderate/severe THV deterioration to better understand their contribution to the primary endpoint. If non-inferiority is proven for the primary composite endpoint, a split alfa is used to test for superiority if possible (alfa=0.025) and to test secondary safety and efficacy endpoints (Total alfa=0.025 for these). The composite endpoint will be re-analyzed after 3-, 5- and 10-year as superiority analyses.
Time frame: 1-year, 3-year, 5-year, 10-year
TAVI-related complications
conversion to open surgery during implantation, unplanned use of cardiopulmonary support (CPS), coronary artery obstruction, ventricular septal perforation, mitral valve apparatus damage or dysfunction, cardiac tamponade / pericardial effusion resulting in pericardiocentesis, valve embolization, valve migration, need for TAVI-in-TAVI deployment, using VARC-3 criteria 10, or annulus rupture, aortic rupture/perforation, aortic dissection, or other shunts than VSD.
Time frame: 7-days
Proportion with successful implantation of the chosen valve.
This means no need for more than 1 TAVI valve, no change to another valve than planned during the procedure because it was impossible to implant the valve planned, and no conversion to surgery or procedure-related death.
Time frame: 7-days
SMART criteria for bioprosthetic valve dysfunction through 12 months
composed of the following components: (1) hemodynamic structural valve dysfunction, defined as aortic valve mean gradient ≥ 20 mmHg at any time up to the 12-month visit echo; (2) nonstructural valve dysfunction, defined as severe prosthesis-patient mismatch or ≥ moderate total aortic regurgitation at any time up to the 12-month visit echo; (3) clinical valve thrombosis; (4) endocarditis; or (5) aortic valve reintervention.
Time frame: 1-year
Pacemaker-implantation
New pace-maker implantation in pacemaker-naive patients.
Time frame: 1-year
Vascular and access-related complications (exploratory only)
Major vascular access site and access-related complications resulting in endovascular or open surgery using VARC-3 criteria
Time frame: 30-days
Bleeding and transfusion (exploratory only)
Major bleeding resulting in drop in hgb-level ≥1.86 mmol/l and/or erythrocyte transfusion ≥ 2 units, modified from BARC type 3-5 criteria
Time frame: 30-days
Endocarditis (exploratory only)
According to VARC-3 criteria.
Time frame: 30-day, 1-year, 3-year, 5-year, 10-year
Reoperation (exploratory only)
Transcatheter Aortic Valve Intervention, Surgical Aortic Valve Intervention or Balloon Angioplasty
Time frame: 30-day, 1-year, 3-year, 5-year, 10-year
Moderate/severe prosthesis-patient mismatch (exploratory only)
Effective Orifice Area (EOA)/body surface area ≤0.85 cm2/m2 if BMI\<30 kg/cm2 or \<=0.70 cm2/m2 if BMI\>=30 kg/cm2., according to VARC-3 criteria.
Time frame: 30-day
Mean gradient (exploratory only)
Aortic mean gradient, mmHg, as evaluated by Echocardiograpy Core-laboratory.
Time frame: 30-day, 1-year, 3-year, 5-year, 10-year
Pacemaker-implantation (exploratory only)
New pacemaker in pacemaker naive-patients.
Time frame: 30-day prior to TAVI, 30-day, 1-year, 3-year, 5-year, 10-year
Readmission for congestive heart failure (exploratory only)
Adjudicated. Only monitored until first confirmed case.
Time frame: 30-day, 1-year, 3-year, 5-year, 10-year.
AMI (exploratory only)
Acute Myocardial Infarction. Adjudicated. Only monitored until first confirmed case.
Time frame: 30-day, 1-year, 3-year, 5-year, 10-year.
Revascularization (exploratory only)
PCI (Percutaneous coronary intervention) CABG (Coronary Artery Bypass Grafting), not scheduled before TAVI
Time frame: 30-day, 1-year, 3-year, 5-year, 10-year.
Atrial fibrillation (exploratory only)
Newly diagnosed atrial fibrillation/flutter
Time frame: 30-day, 1-year, 3-year, 5-year, 10-year.
Kidney injury (exploratory only)
Increase in renal creatinine level more than to ≥200% (AKIN stage 2-3, VARC-3 criteria) or resulting in dialysis (AKIN stage 4) according to VARC-3 criteria.
Time frame: 30-day
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — We are willing to collaborate in meta-analyses based on individual data where department of epidemiology, Aarhus University Hospital will be responsible for data-analyses.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: Available now. Analytic will be made available when final statistical analyses performed.
Access criteria: Contact primary investigator
Started Aug 2024 (actual). Primary completion is estimated for Jul 2027, 35 months after the start.
Of 177 non-industry interventional studies with no phase under Aortic Valve Stenosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 79. This study's planned 35 months is below that.
Counting every sponsor, half of 288 studies reached it within 33 months; a quarter within 18 and three quarters within 71.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Christian Juhl Terkelsen